Genetics of the Acute Response to Oral Semaglutide (GAROS)
Status:
Not yet recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
The study aims to investigate the genetic basis of the response to short-term (3 months)
orally administered semaglutide treatment, in terms of improving metabolic parameters,
including the hormonal response to a standardized meal, and changes in body composition and
liver steatosis. In the study, parameters such as fasting and 2-hour glucose during OGTT,
HbA1c, body fat mass, body weight, total cholesterol, HDL and LDL, triglycerides, HOMA-IR,
Matsuda Index and liver steatosis will be assessed. All the patients will undergo genome-wide
genotyping. Moreover, in a subset of participants, muscle and fat biopsies will be performed,
before and after the treatment, and liver, muscle and pancreas fat content will be assessed
using MRI.